Literature DB >> 6303376

Concentration effect modelling with converting enzyme inhibitors in man.

A W Kelman, J L Reid, J A Millar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6303376      PMCID： PMC1427814          DOI： 10.1111/j.1365-2125.1983.tb01542.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  7 in total

1.  The measurement of angiotensin-converting enzyme in subjects receiving captopril.

Authors:  J E Roulston; G A MacGregor
Journal:  N Engl J Med       Date:  1980-08-14       Impact factor: 91.245

2.  Opposite effects of captopril on angiotensin I-converting enzyme 'activity' and 'concentration'; relation between enzyme inhibition and long-term blood pressure response.

Authors:  F Boomsma; J H de Bruyn; F H Derkx; M A Schalekamp
Journal:  Clin Sci (Lond)       Date:  1981-05       Impact factor: 6.124

3.  Disposition of captopril in normal subjects.

Authors:  K J Kripalani; D N McKinstry; S M Singhvi; D A Willard; R A Vukovich; B H Migdalof
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

4.  Captopril treatment: inter-dose variations in renin, angiotensins I and II, aldosterone and blood pressure.

Authors:  A B Atkinson; A M Cumming; J J Brown; R Fraser; B Leckie; A F Lever; J J Morton; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

5.  Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521.

Authors:  J A Millar; F H Derkx; K McLean; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

6.  Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system.

Authors:  J Biollaz; J L Schelling; B Jacot Des Combes; D B Brunner; G Desponds; H R Brunner; E H Ulm; M Hichens; H J Gomez
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

7.  Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril.

Authors:  B Waeber; H R Brunner; D B Brunner; A L Curtet; G A Turini; H Gavras
Journal:  Hypertension       Date:  1980 Mar-Apr       Impact factor: 10.190
  7 in total
  9 in total

1.  The description and prediction of antihypertensive drug response: an individualised approach.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

Review 2.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

3.  The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment.

Authors:  E J Begg; R A Robson; R R Bailey; K L Lynn; G J Frank; S C Olson
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

4.  Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects.

Authors:  P U Witte; R Irmisch; P Hajdú; H Metzger
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Pharmacodynamic, pharmacokinetic and humoral effects of oral zabicipril, an angiotensin converting enzyme inhibitor in normotensive man.

Authors:  N J MacDonald; D M Hughes; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

6.  Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.

Authors:  N Hockings; A A Ajayi; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

Review 7.  Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.

Authors:  G G Belz; W Kirch; C H Kleinbloesem
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

8.  Steady-state pharmacokinetics and pharmacodynamics of benazeprilat in spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats.

Authors:  S LeRoy; B Berner
Journal:  Pharm Res       Date:  1991-07       Impact factor: 4.200

9.  Pharmacokinetic-pharmacodynamic model relating zabiciprilat plasma concentrations to brachial and femoral haemodynamic effects in normotensive volunteers.

Authors:  E Bellissant; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.